Tumour-specific therapeutic adenovirus vectors: repression of transgene expression in healthy cells by endogenous p53
- 1 February 2001
- journal article
- Published by Springer Nature in Gene Therapy
- Vol. 8 (4) , 274-281
- https://doi.org/10.1038/sj.gt.3301403
Abstract
At the forefront of medicine, Gene Therapy brings you the latest research into genetic and cell-based technologies to treat disease. It also publishes Progress & Prospects reviews and News and Commentary articles, which highlight the cutting edge of the field.Keywords
This publication has 27 references indexed in Scilit:
- Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954Cancer Gene Therapy, 2000
- Targeting gene expression to tumor cells with loss of wild-type p53 functionCancer Gene Therapy, 2000
- p53 Represses CAAT Enhancer-binding Protein (C/EBP)-dependent Transcription of the Albumin GeneJournal of Biological Chemistry, 1999
- A strategy for enhancing the transcriptional activity of weak cell type-specific promotersGene Therapy, 1998
- Progress in Transcriptionally Targeted and Regulatable Vectors for Genetic TherapyHuman Gene Therapy, 1997
- Targeted gene delivery by tropism-modified adenoviral vectorsNature Biotechnology, 1996
- Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell typesNature Biotechnology, 1996
- Inducible gene expression systems for higher eukaryotic cellsCurrent Opinion in Biotechnology, 1994
- Inhibition of gene expression with ribozymesCellular and Molecular Neurobiology, 1994
- Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis.Genes & Development, 1993